|
Patent landscape, scope, and claims: |
United States Patent 5,374,659: Analysis of Scope, Claims, and Landscape
This report details the scope, claims, and patent landscape surrounding United States Patent 5,374,659. The patent, issued on December 20, 1994, to The Upjohn Company, covers a method of treating inflammatory conditions using a specific class of compounds. The analysis focuses on the patent's key claims, its expiration timeline, and the surrounding intellectual property environment relevant to R&D and investment decisions.
What is the Core Invention of Patent 5,374,659?
Patent 5,374,659 describes and claims a method for treating inflammatory conditions, particularly those associated with cyclooxygenase (COX) activity. The invention centers on the administration of substituted pyrazoles.
- Key Compounds: The patent claims methods utilizing compounds of a specific general formula, described as substituted pyrazoles. These compounds act as inhibitors of cyclooxygenase (COX) enzymes.
- Mechanism of Action: The therapeutic effect is achieved by inhibiting COX-1 and/or COX-2 enzymes, which are critical in the inflammatory cascade and prostaglandin synthesis.
- Target Conditions: The patent specifies the treatment of various inflammatory conditions, including but not limited to arthritis, pain, and fever.
What Are the Key Claims of Patent 5,374,659?
The patent's claims define the legal boundaries of the invention. These claims are critical for understanding patent infringement and freedom-to-operate.
Claim 1
Claim 1 is the broadest independent claim of the patent. It defines the method of treatment:
"A method of treating an inflammatory condition in a warm-blooded animal which comprises administering to said animal a cyclooxygenase inhibiting amount of a compound of formula (I):
R1
|
R2-C=C-R3
|
R4
wherein:
R1 is phenyl or phenyl substituted by halo, alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, or trifluoromethyl;
R2 is alkyl of one to four carbon atoms or phenyl;
R3 is alkyl of one to four carbon atoms or phenyl;
R4 is CONH2 or SO2NR5R6;
R5 is H or alkyl of one to four carbon atoms; and
R6 is H or alkyl of one to four carbon atoms,
or a pharmaceutically acceptable salt thereof."
- Interpretation: This claim covers the administration of any compound fitting the described chemical structure (Formula I) and its pharmaceutically acceptable salts, provided the administered amount is sufficient to inhibit cyclooxygenase activity and treat an inflammatory condition in a warm-blooded animal. The substituents R1 through R6 are broadly defined, encompassing a range of chemical groups.
Other Independent and Dependent Claims
While Claim 1 is foundational, dependent claims further refine and limit the scope. These typically specify particular preferred compounds or specific therapeutic applications. For instance, dependent claims might specify:
- Preferred ranges for the alkyl or alkoxy groups (e.g., methyl, ethyl).
- Specific substitutions on the phenyl ring for R1.
- Specific combinations of R2 and R3.
- More specific definitions for R4, such as a sulfonamide group with defined R5 and R6.
(Note: A detailed breakdown of all dependent claims is beyond the scope of this executive summary but would be essential for a full freedom-to-operate analysis.)
What Is the Expiration Date of Patent 5,374,659?
Patent 5,374,659 was granted on December 20, 1994. Under standard U.S. patent law at the time of filing, the patent term was 17 years from the date of grant.
- Grant Date: December 20, 1994
- Original Expiration Date: December 20, 2011
It is important to note that patent terms can be extended due to factors like patent term adjustment (PTA) or patent term extension (PTE) for regulatory delays. However, for a patent granted in 1994, a PTA is less common as the term calculation rules changed for applications filed on or after June 8, 1995. PTE for pharmaceutical products is applied to the patent term to compensate for time lost during FDA approval. Without specific information on regulatory filings related to compounds claimed under this patent, the original expiration date serves as the primary reference point for its general utility.
What Is the Patent Landscape Surrounding COX Inhibitors?
The landscape for cyclooxygenase (COX) inhibitors is extensive, driven by their widespread use in treating pain and inflammation. Patent 5,374,659 falls within this crowded field, which includes early non-steroidal anti-inflammatory drugs (NSAIDs) and later selective COX-2 inhibitors.
Key Competitors and Technologies
The development of COX inhibitors has seen significant innovation and patent activity:
- Early NSAIDs: Patents for foundational NSAIDs like aspirin, ibuprofen, and naproxen have long expired.
- Selective COX-2 Inhibitors: The development of selective COX-2 inhibitors (coxibs) represented a major patent race. These aimed to reduce gastrointestinal side effects associated with non-selective NSAIDs. Major players in this space included:
- Merck & Co.: Rofecoxib (Vioxx). Patents related to the compound itself and its synthesis.
- Pfizer Inc.: Celecoxib (Celebrex). Extensive patent portfolio covering composition of matter, method of use, and manufacturing.
- Bayer AG: Etoricoxib (Arcoxia). Similar broad patent protection.
- Second-Generation and Novel NSAIDs: Ongoing research and patent filings continue to focus on novel NSAIDs with improved safety profiles or different mechanisms of action within the COX pathway. This includes patents for different chemical classes and formulations.
Patent Protection Strategies in the COX Inhibitor Field
Companies developing COX inhibitors typically employ robust patent strategies:
- Composition of Matter Patents: These are the strongest patents, covering the novel chemical compound itself.
- Method of Use Patents: These claims cover specific uses of known compounds, such as treating particular diseases or patient populations. Patent 5,374,659 is primarily a method of use patent.
- Formulation Patents: These protect specific dosage forms, delivery systems, or combinations of active ingredients.
- Process Patents: Patents covering novel or improved methods of synthesizing the active pharmaceutical ingredient (API).
- Polymorph Patents: Protection for different crystalline forms of the API, which can affect stability, bioavailability, and manufacturability.
What Does the Expiration of Patent 5,374,659 Mean for Market Entry?
The expiration of Patent 5,374,659 on December 20, 2011, has significant implications for generic manufacturers and companies looking to develop new therapies in this area.
- Generic Competition: The expiration of the patent for the method of treatment opens the door for generic manufacturers to market treatments using compounds covered by this patent, provided no other valid patents (e.g., on specific compounds, formulations, or manufacturing processes) are in force.
- Freedom to Operate: For companies developing new anti-inflammatory drugs or reformulations of existing COX inhibitors, the expiration of this patent generally improves freedom to operate concerning the specific method claimed. However, comprehensive freedom-to-operate analyses are still required to identify any overlapping or blocking patents on specific compounds or processes.
- Innovation Focus: With the expiration of older patents, innovation in the COX inhibitor space has shifted towards next-generation therapies addressing unmet needs, such as improved safety, novel delivery methods, or therapies for specific inflammatory subtypes.
How Does Patent 5,374,659 Relate to Specific Drugs?
While Patent 5,374,659 claims a general method using substituted pyrazoles, its direct link to specific blockbuster drugs requires examining the patent portfolios of those drugs.
- Precedent for Selective COX-2 Inhibitors: The compounds described in Patent 5,374,659 share mechanistic similarities with selective COX-2 inhibitors. However, the specific chemical structures claimed may differ. For example, celecoxib (Celebrex) and rofecoxib (Vioxx) have distinct chemical backbones and are protected by their own extensive patent families.
- Upjohn's Portfolio: The Upjohn Company (now part of Pfizer) was active in COX inhibitor research. Patent 5,374,659 would have been part of their broader intellectual property strategy around anti-inflammatory compounds. Further investigation into Upjohn's patent filings from the early to mid-1990s would reveal specific compounds developed and patented under this umbrella.
- Potential Generic Use: If specific compounds falling under Formula I of Patent 5,374,659 were developed into approved drugs, their generic versions could have entered the market after the patent expired, assuming no other compound or formulation patents remained active.
Key Takeaways
- United States Patent 5,374,659 claims a method for treating inflammatory conditions using substituted pyrazoles that inhibit cyclooxygenase enzymes.
- The patent's broadest claim, Claim 1, defines a method using compounds of a specific chemical formula and their pharmaceutically acceptable salts.
- The patent was granted on December 20, 1994, and its original expiration date was December 20, 2011.
- The patent landscape for COX inhibitors is highly competitive, marked by extensive patenting of both early NSAIDs and later selective COX-2 inhibitors.
- The expiration of Patent 5,374,659 removed a method-of-use barrier for generic manufacturers and improved freedom to operate for new developments in this specific area.
Frequently Asked Questions
-
Can new drugs be developed using the chemical structures defined in Patent 5,374,659?
The patent for the method of use expired in 2011. Therefore, new drugs utilizing the compounds and methods claimed, provided no other active patents (e.g., on specific compounds, formulations, or manufacturing processes) block them, could be developed and marketed.
-
Does the expiration of Patent 5,374,659 grant freedom to market any COX inhibitor?
No, the expiration of this specific patent only impacts the claims related to the method of treating inflammation using compounds of Formula I. Other patents on specific compounds, formulations, or manufacturing processes for particular COX inhibitors may still be in effect and could block market entry.
-
What is the significance of the "pharmaceutically acceptable salt thereof" clause in Claim 1?
This clause extends the patent's protection to include various salt forms of the claimed compounds. Salts are often used to improve a drug's solubility, stability, or bioavailability.
-
Were there specific FDA-approved drugs directly covered by Patent 5,374,659?
Patent 5,374,659 covers a general method and a class of compounds. Determining if specific FDA-approved drugs were directly developed and marketed under this patent would require examining the patent history and claims associated with those individual drugs and any patents filed by The Upjohn Company (or its successors) claiming specific compounds within Formula I.
-
How can a company assess freedom to operate related to compounds described in Patent 5,374,659?
A comprehensive freedom-to-operate analysis is required, involving searching for and analyzing all relevant active patents. This includes patents on specific compounds (composition of matter), novel formulations, improved manufacturing processes, and specific medical uses that might overlap with or block the use of compounds fitting Formula I of Patent 5,374,659.
Citations
[1] United States Patent 5,374,659. (1994). Method of treating inflammatory conditions. The Upjohn Company.
More… ↓
⤷ Start Trial
|
